8 completed, 3 recruiting, 2 unknown. 13 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Completed 8, Recruiting 3, Unknown 2 |
| Phase 1 | 2 | Completed 1, Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Lung Neoplasm: new trials by email Literature Review of Lung Neoplasm trials Research Report on Lung Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I) R-DXD, I-DXD, Docetaxel - Lung Neoplasm | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 144 | 2025-05-28 | 2026-10-07 |
| DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations Trastuzumab, Pertuzumab - Haematological Malignancy, Colorectal Neoplasms | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2023-03-07 | 2025-12-02 |
| A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere) - Advanced Solid Tumors, Genital Neoplasm, Female | Phase 1 / Phase 2 | Recruiting | Marengo Therapeutics, Inc. | 366 | 2023-01-04 | 2026-08-11 |
| Brazilian Lung Immunotherapy Study Alectinib, Pembrolizumab, Nivolumab - Lung Neoplasm | Phase 2 | Completed | Hospital Israelita Albert Einstein | 154 | 2020-01-01 | 2023-10-11 |
| Prophylactic Risedronate for Patients With Peripheral Lung Tumors Treated With SBRT risedronate, Matching placebo - Lung Neoplasm | Phase 2 | Completed | Wake Forest University Health Sciences | 84 | 2019-07-12 | 2026-08-03 |
| Efficacy and Safety of Anlotinib as Maintenance Treatment After First-line Chemotherapy in SCLC Anlotinib Hydrochloride - Carcinoma, Lung Neoplasm | Phase 2 | Unknown | First Hospital of Shijiazhuang City | 30 | 2019-01-01 | 2018-12-21 |
| Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative Sintilimab, Anlotinib Hydrochloride - Carcinoma, Non-small Cell Lung Cancer | Phase 2 | Unknown | First Hospital of Shijiazhuang City | 20 | 2018-11-20 | 2018-12-06 |
| Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors pralsetinib (BLU-667) - RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Completed | Hoffmann-La Roche | 590 | 2017-03-17 | 2025-05-31 |
| HA-WBRT-SIB for Brain Metastasis of Lung Cancer HA-WBRT-SIB - Lung Neoplasm, Brain Metastases | Phase 2 | Completed | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 40 | 2016-01-01 | 2024-03-01 |
| Efficacy and Safety of Adjuvant Pemetrexed Plus Cisplatin for Adenocarcinoma of Lung Pemebit, Cisplatin - Adenocarcinoma, Lung Neoplasm | Phase 2 | Completed | Chonnam National University Hospital | 106 | 2015-09-01 | 2021-08-06 |
| Hypofractionated Radiotherapy for Limited Stage Small Cell Lung Cancer Hypofractionated Chest Radiotherapy - Lung Neoplasm, Small Cell Carcinoma | Phase 2 | Completed | AHS Cancer Control Alberta | 2 | 2009-06-01 | 2016-02-22 |
| Oral Vinorelbine and Cisplatin and Concurrent Radiotherapy After Induction Chemotherapy in Locally Advanced NSCLC. Vinorelbine - Lung Neoplasm | Phase 2 | Completed | University Hospital, Brest | 60 | 2006-02-01 | 2009-07-28 |
| Phase II Study of Lucanix™ in Patients With Stages II-IV Non-Small Cell Lung Cancer Lucanix - Lung Neoplasm, Carcinoma, Bronchogenic | Phase 2 | Completed | NovaRx Corporation | 75 | 2003-03-01 | 2010-07-29 |
Lung Neoplasms (13) · Carcinoma (4) · Carcinoma, Non-Small-Cell Lung (4) · Colorectal Neoplasms (3) · Neoplasms (3) · Small Cell Lung Carcinoma (3) · Adenocarcinoma (2) · Carcinoma, Bronchogenic (2) · Gastrointestinal Neoplasms (2) · Head and Neck Neoplasms (2) · Neoplasms by Site (2) · Urinary Bladder Neoplasms (2) · Abdominal Neoplasms (1) · Adenocarcinoma of Lung (1) · Adenocarcinoma, Papillary (1)
Lung Diseases (12) · Respiratory Tract Diseases (12) · Respiratory Tract Neoplasms (12) · Thoracic Neoplasms (12) · Neoplasms by Site (11) · Neoplasms (10) · Bronchial Neoplasms (6) · Neoplasms by Histologic Type (6) · Neoplasms, Glandular and Epithelial (6) · Carcinoma, Bronchogenic (5) · Carcinoma (3) · Rectal Diseases (3) · Adenocarcinoma (2) · Biliary Tract Diseases (2) · Colonic Diseases (2)
Docetaxel (2) · anlotinib (2) · Cisplatin (1) · Erlotinib Hydrochloride (1) · Irinotecan (1) · Nivolumab (1) · Pemetrexed (1) · Risedronic Acid (1) · Trastuzumab (1) · Vinorelbine (1) · alectinib (1) · belagenpumatucel L (1) · pembrolizumab (1) · pertuzumab (1) · pralsetinib (1)
First Hospital of Shijiazhuang City (2) · AHS Cancer Control Alberta (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Cancer Research UK (1) · Chonnam National University Hospital (1) · Hoffmann-La Roche (1) · Hospital Israelita Albert Einstein (1) · Marengo Therapeutics, Inc. (1) · Merck Sharp & Dohme LLC (1) · NovaRx Corporation (1) · University Hospital, Brest (1) · Wake Forest University Health Sciences (1)
China (5) · United States (5) · France (3) · Spain (3) · Canada (2) · Germany (2) · Italy (2) · South Korea (2) · United Kingdom (2) · Belgium (1) · Brazil (1) · Chile (1) · Greece (1) · Hong Kong (1) · Hungary (1)
Yan Zhang, M.D. (2) · Diogo Gomes, MD (1) · Habib Fakhrai, PhD (1) · Matthew Krebs, Dr (1) · Michael Farris, MD (1) · Young-Chul Kim, MD, PhD (1)
PMID 16945766, PMID 16957145, PMID 16966690, PMID 23161898, PMID 34118197, PMID 34118198, PMID 35715405, PMID 35962206, PMID 36090637, PMID 37282666, PMID 37916501, PMID 37934000, PMID 38009200, PMID 39060968, PMID 40639400, PMID 41886723
2016 (1), 2023 (1), P30CA012197 (1)